Pox­el takes write­down on NASH drug as it con­tin­ues lay­offs, search for cash

France’s Pox­el still be­lieves that it can blaze a path for­ward in rare dis­eases — but be­fore it can con­vince in­vestors or part­ners of that, it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.